Evidence map›Paper›PMID 38808258›Full record

ArticleFrontiers in pharmacology2024

Salidroside alleviates cholestasis-induced liver fibrosis by inhibiting hepatic stellate cells via activation of the PI3K/AKT/GSK-3β signaling pathway and regulating intestinal flora distribution.

Xin Wang, Shuxia Cao, Yuan Huang, Liangchang Li, Dongyuan Xu, Lan Liu

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Quercetin alleviates CClBiochemistry and biophysics reports · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin Wang *Key Laboratory of Cellular Function and Pharmacology of Jilin Province, Yanbian University, Yanji, China.
Shuxia Cao *Key Laboratory of Cellular Function and Pharmacology of Jilin Province, Yanbian University, Yanji, China.
Yuan HuangKey Laboratory of Cellular Function and Pharmacology of Jilin Province, Yanbian University, Yanji, China.
Liangchang LiKey Laboratory of Cellular Function and Pharmacology of Jilin Province, Yanbian University, Yanji, China.
Dongyuan XuKey Laboratory of Cellular Function and Pharmacology of Jilin Province, Yanbian University, Yanji, China.
Lan LiuKey Laboratory of Cellular Function and Pharmacology of Jilin Province, Yanbian University, Yanji, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salidroside (SAL), a phenylpropanoid bioactive compound, has various pharmacological properties, including antioxidant, anti-inflammatory, and hepatoprotective effects. However, the pharmacological effects and mechanisms of action of SAL on cholestatic liver injury are unclear. This study investigated the mechanism and effects of salidroside (SAL) on intestinal flora distribution and hepatic stellate cell (HSC) activation in cholestatic hepatic fibrosis. Bile duct ligation was used to cause cholestasis BALB/c mice. The therapeutic efficacy of SAL in liver fibrosis was assessed via serum/tissue biochemical analyses and liver tissue hematoxylin and eosin and Masson staining. Inflammation and oxidative stress were analyzed using enzyme-linked immunosorbent assay and western blotting. HSC were activated

Indexed as

cholestatic liver fibrosishepatic stellate cellsintestinal floraPI3K/Akt/GSK-3β pathwaysalidroside

Identifiers

PMID38808258
PMCPMC11130389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.